HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 285/6/H2500    most recent 00432.2003v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (24) Citing Articles via Google Scholar Google Scholar Articles by Garner, L. B. Articles by Giroir, B. P. Search for Related Content PubMed PubMed Citation Articles by Garner, L. B. Articles by Giroir, B. P.

Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor

¹Department of Pediatrics, University of Texas Southwestern, Dallas 75390-9063; ²Department of Surgery, University of Texas Southwestern, Dallas 75390-9160; ³Department of Pathology, University of Texas Southwestern, Dallas 75390-9072; and ⁴Department of Cardiothoracic Surgery, University of Texas Southwestern, Dallas, Texas 75390-9130

Submitted 8 May 2003 ; accepted in final form 20 August 2003

Macrophage migration inhibitory factor (MIF) is a pluripotent proinflammatory cytokine that is ubiquitously expressed in organs, including the heart. However, no specific role for MIF in modulating cardiac performance has yet been described. Therefore, we examined cardiac MIF expression in mice after LPS challenge (4 mg/kg) and tested the hypothesis that MIF is a mediator of LPS-induced cardiac dysfunction. Western blots of whole heart lysates, as well as immunohistochemistry, documented constitutive MIF protein expression in the heart. Cardiac MIF protein levels significantly decreased after LPS challenge, reaching a nadir at 12 h, and then returned to baseline by 24 h. This pattern was consistent with MIF release from cytoplasmic stores after endotoxin challenge. After release of protein, MIF mRNA levels increased 24–48 h postchallenge. To determine the functional consequences of MIF release, we treated LPS-challenged mice with anti-MIF neutralizing antibodies or isotype control antibodies. Anti-MIF-treated animals had significantly improved cardiac function, as evidenced by a significant improvement in left ventricular (LV) fractional shortening percentage at 8, 12, 24, and 48 h after endotoxin challenge. In support of these findings, perfusion of isolated beating mouse hearts (Langendorff preparation) with recombinant MIF (20 ng/ml) led to a significant decrease in both systolic and diastolic performance [LV pressure (LVP), positive and negative first derivative of LVP with respect to time, and rate of LVP rise at developed pressure of 40 mmHg]. This study demonstrates that MIF mediates LPS-induced cardiac dysfunction and suggests that MIF should be considered a pharmacological target for the treatment of cardiac dysfunction in sepsis and potentially other cardiac diseases.

cardiac dysfunction; innate immunity; sepsis; lipopolysaccharide

This article has been cited by other articles:

				A. Zernecke, J. Bernhagen, and C. Weber Macrophage Migration Inhibitory Factor in Cardiovascular Disease Circulation, March 25, 2008; 117(12): 1594 - 1602. [Abstract] [Full Text] [PDF]

				D. Carlson, D. L. Maass, D. J. White, J. Tan, and J. W. Horton Antioxidant vitamin therapy alters sepsis-related apoptotic myocardial activity and inflammatory responses Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2779 - H2789. [Abstract] [Full Text] [PDF]

				K. V. Ramana, M. S. Willis, M. D. White, J. W. Horton, J. M. DiMaio, D. Srivastava, A. Bhatnagar, and S. K. Srivastava Endotoxin-Induced Cardiomyopathy and Systemic Inflammation in Mice Is Prevented by Aldose Reductase Inhibition Circulation, October 24, 2006; 114(17): 1838 - 1846. [Abstract] [Full Text] [PDF]

				T. Ha, F. Hua, D. Grant, Y. Xia, J. Ma, X. Gao, J. Kelley, D. L. Williams, J. Kalbfleisch, I. W. Browder, et al. Glucan phosphate attenuates cardiac dysfunction and inhibits cardiac MIF expression and apoptosis in septic mice Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1910 - H1918. [Abstract] [Full Text] [PDF]

				L. E. Lehmann, S. Schroeder, W. Hartmann, O. Dewald, M. Book, S. U. Weber, J.-C. Schewe, and F. Stuber A single nucleotide polymorphism of macrophage migration inhibitory factor is related to inflammatory response in coronary bypass surgery using cardiopulmonary bypass. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 59 - 63. [Abstract] [Full Text] [PDF]

				A. D. Niederbichler, L. M. Hoesel, M. V. Westfall, H. Gao, K. R. Ipaktchi, L. Sun, F. S. Zetoune, G. L. Su, S. Arbabi, J. V. Sarma, et al. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction J. Exp. Med., January 23, 2006; 203(1): 53 - 61. [Abstract] [Full Text] [PDF]

				F. Chagnon, C. N. Metz, R. Bucala, and O. Lesur Endotoxin-Induced Myocardial Dysfunction: Effects of Macrophage Migration Inhibitory Factor Neutralization Circ. Res., May 27, 2005; 96(10): 1095 - 1102. [Abstract] [Full Text] [PDF]

				M. S. Willis, D. L. Carlson, J. M. DiMaio, M. D. White, D. J. White, G. A. Adams IV, J. W. Horton, and B. P. Giroir Macrophage migration inhibitory factor mediates late cardiac dysfunction after burn injury Am J Physiol Heart Circ Physiol, February 1, 2005; 288(2): H795 - H804. [Abstract] [Full Text] [PDF]